We further validated that SLC7A6 was significantly up-regulated in cisplatin resistant bladder cancer cells versus cisplatin sensitive bladder cancer cells while the expression of SLC7A6 in CD8 + T cells remained relatively at minimum level. Here, SLC7A6 is linked to urinary bladder carcinoma.